Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome.

Hartley SL, Handen BL, Devenny DA, Hardison R, Mihaila I, Price JC, Cohen AD, Klunk WE, Mailick MR, Johnson SC, Christian BT.

Brain. 2014 Sep;137(Pt 9):2556-63. doi: 10.1093/brain/awu173.

2.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group..

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125.

3.

Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.

Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.

Brain. 2012 Jul;135(Pt 7):2115-25. doi: 10.1093/brain/aws113.

4.

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.

Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A.

Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349.

5.

Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y.

Brain. 2013 Oct;136(Pt 10):3004-17. doi: 10.1093/brain/awt195.

6.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group..

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383.

7.

Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.

Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD; AIBL Research Group..

J Alzheimers Dis. 2014;40(1):95-104. doi: 10.3233/JAD-131802.

PMID:
24334723
8.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative..

Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062.

9.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9.

PMID:
22926714
10.

Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults.

Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, McDade E, Price JC, Mathis CA, Klunk WE.

Am J Geriatr Psychiatry. 2015 Sep;23(9):985-93. doi: 10.1016/j.jagp.2015.01.008.

11.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112.

12.

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.

Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.

Brain. 2016 Mar;139(Pt 3):922-36. doi: 10.1093/brain/awv404.

13.

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.

Arch Neurol. 2009 Jan;66(1):60-7. doi: 10.1001/archneurol.2008.511.

14.

Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.

Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, Pimlott S, Hutchinson PJ, Tavares A, Canales R, Mathis CA, Klunk WE, Aigbirhio FI, Coles JP, Baron JC, Pickard JD, Fryer TD, Stewart W, Menon DK.

JAMA Neurol. 2014 Jan;71(1):23-31. doi: 10.1001/jamaneurol.2013.4847.

15.

Association of lifetime cognitive engagement and low β-amyloid deposition.

Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, Wilson RS, Jagust WJ.

Arch Neurol. 2012 May;69(5):623-29.

16.

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.

Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, Mathis CA, Price JC, Klunk WE.

Alzheimers Dement. 2012 Nov;8(6):496-501. doi: 10.1016/j.jalz.2011.09.229.

17.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative..

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277.

18.

Amyloid imaging of Lewy body-associated disorders.

Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, Hershey T, Perlmutter JS.

Mov Disord. 2010 Nov 15;25(15):2516-23. doi: 10.1002/mds.23393.

19.
20.

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.

Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB; Biomarkers Consortium PET Radioligand Project Team..

Brain. 2013 Jul;136(Pt 7):2228-38. doi: 10.1093/brain/awt145.

Items per page

Supplemental Content

Support Center